Literature DB >> 20236686

The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer.

Akihiko Kawahara1, Koichi Azuma, Satoshi Hattori, Kazutaka Nakashima, Yuji Basaki, Jun Akiba, Sinzo Takamori, Hisamichi Aizawa, Takashi Yanagawa, Hiroto Izumi, Kimitoshi Kohno, Suminori Kono, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono.   

Abstract

Patients with non-small cell lung cancer harboring mutations in the epidermal growth factor receptor gene, including delE746-A750 and L858R, are highly sensitive to therapy with epidermal growth factor receptor-targeting drugs, such as gefitinib and erlotinib, in comparison with those harboring wild-type epidermal growth factor receptor. It remains unclear how such epidermal growth factor receptor mutations are induced. In this study, we examined whether 8-hydroxy-2'-deoxyguanosine, a representative oxygen nucleotide of DNA, could play a role in activating mutations of the epidermal growth factor receptor gene and also whether Y-box binding protein-1 and 8-oxoguanine DNA glycosylase that are involved in repair of oxidative stimuli-induced DNA damages could play any role in epidermal growth factor receptor activating mutations. Immunohistochemistry was used to evaluate the expression of 8-hydroxy-2'-deoxyguanosine, Y-box binding protein-1, and 8-oxoguanine DNA glycosylase in patients with non-small cell lung cancer (N = 170). We analyzed mutations of delE746-A750 and L858R in the epidermal growth factor receptor gene using peptide nucleic acid-locked nucleic acid polymerase chain reaction clamping. In non-small cell lung cancer patients, nuclear 8-hydroxy-2'-deoxyguanosine expression was strongly associated with these epidermal growth factor receptor mutations. Furthermore, nuclear expression of Y-box binding protein-1 was inversely associated with epidermal growth factor receptor mutations; but nuclear expression of 8-oxoguanine DNA glycosylase was not. Among 51 patients who were treated with gefitinib, progression-free survival was substantially better when 8-hydroxy-2'-deoxyguanosine expression was positive, when epidermal growth factor receptor mutations were present, and when nuclear Y-box binding protein-1 expression was negative. Thus, activating mutations of the epidermal growth factor receptor gene in non-small cell lung cancer were closely associated with a decrease in the damage repair process for 8-hydroxy-2'-deoxyguanosine in oxidized DNA. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20236686     DOI: 10.1016/j.humpath.2009.12.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Protective effects of amifostine, curcumin, and melatonin against cisplatin-induced acute kidney injury.

Authors:  Filiz Mercantepe; Tolga Mercantepe; Atilla Topcu; Adnan Yılmaz; Levent Tumkaya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-02       Impact factor: 3.000

2.  Radical decisions in cancer: redox control of cell growth and death.

Authors:  Rosa M Sainz; Felipe Lombo; Juan C Mayo
Journal:  Cancers (Basel)       Date:  2012-04-25       Impact factor: 6.639

3.  The association between human papillomavirus presence and epidermal growth factor receptor mutations in Asian patients with non-small cell lung cancer.

Authors:  Hengrui Liang; Zhenkui Pan; Xiuyu Cai; Wei Wang; Chengye Guo; Jiaxi He; Yuehan Chen; Zhichao Liu; Bo Wang; Jianxing He; Wenhua Liang
Journal:  Transl Lung Cancer Res       Date:  2018-06

4.  Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.

Authors:  Fumie Yamashita; Koichi Azuma; Tsukasa Yoshida; Kazuhiko Yamada; Akihiko Kawahara; Satoshi Hattori; Hiroaki Takeoka; Yoshiaki Zaizen; Tomotaka Kawayama; Masayoshi Kage; Tomoaki Hoshino
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.